Deerfield Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
Sell
-1,969,225
Closed -$6.36M 101
2017
Q1
$6.36M Buy
+1,969,225
New +$4.84M 0.25% 82
2016
Q4
Sell
-1,935,942
Closed -$3.02M 110
2016
Q3
$3.02M Hold
1,935,942
0.14% 71
2016
Q2
$2.58M Sell
1,935,942
-2,462,920
-56% -$11.5M 0.1% 83
2016
Q1
$23.2M Buy
4,398,862
+93,574
+2% +$573K 0.99% 39
2015
Q4
$33.8M Buy
4,305,288
+394,567
+10% +$3.4M 1.37% 24
2015
Q3
$33M Buy
3,910,721
+1,445,592
+59% +$13.3M 1.28% 28
2015
Q2
$27M Sell
2,465,129
-1,503,026
-38% -$19.3M 0.9% 40
2015
Q1
$55.5M Buy
3,968,155
+110,350
+3% +$1.69M 1.8% 13
2014
Q4
$65.2M Sell
3,857,805
-25,000
-0.6% -$364K 2.34% 11
2014
Q3
$52.1M Buy
3,882,805
+207,967
+6% +$2.48M 1.9% 13
2014
Q2
$46.8M Sell
3,674,838
-769,189
-17% -$8.01M 1.88% 15
2014
Q1
$52.8M Buy
4,444,027
+462,284
+12% +$6.2M 2.16% 12
2013
Q4
$55M Buy
3,981,743
+1,809,999
+83% +$25.6M 2.85% 8
2013
Q3
$37.9M Sell
2,171,744
-183,219
-8% -$3.51M 1.76% 14
2013
Q2
$38.1M Buy
+2,354,963
New +$72.9M 1.8% 19

Other funds holding INFI

Deerfield Management's INFI Position: Q2 2017 in Review

Deerfield Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q2 2017, closing a stake of 1,969,225 shares — an estimated $6.36M sold.

Deerfield Management first reported a position in INFI in Q2 2013 and held it in 15 quarters. The position peaked at $65.2M in Q4 2014. 74 funds tracked by Wall St. Rank hold INFI as of Q2 2017.

  • Deerfield Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Deerfield Management sold 1,969,225 Infinity Pharmaceuticals, Inc. shares in Q2 2017, an estimated $6.36M.
  • Deerfield Management first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 15 quarters.
  • Deerfield Management's Infinity Pharmaceuticals, Inc. position peaked at $65.2M in Q4 2014.
  • 74 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q2 2017.

Based on Deerfield Management's 13F filing for Q2 2017, filed 14 Aug 2017.